Actively Recruiting
Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
Led by Mansoura University · Updated on 2026-03-16
70
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate the effectiveness and safety of low-intensity shockwave therapy (Li-SWT) for the treatment of overactive bladder (OAB) in adult women. The main questions this study aims to answer are whether Li-SWT improves overactive bladder symptoms and quality of life, and whether these improvements are sustained over a 12-month follow-up period, compared with standard medical therapy. Researchers will compare Li-SWT with oral solifenacin succinate, a commonly used antimuscarinic medication for OAB. Participants will be randomly assigned to receive either Li-SWT once weekly for 8 weeks or solifenacin 5 mg taken orally once daily for 12 months. All participants will complete symptom questionnaires and three-day voiding diaries and will undergo uroflowmetry, post-void residual measurement, and filling cystometry at specified time points during follow-up.
CONDITIONS
Official Title
Low-intensity Shockwave Therapy Versus Solifenacin for the Treatment of Overactive Bladder in Women
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female adults aged 18 years or older
- Overactive bladder symptoms persisting for at least 3 months
- Overactive Bladder Symptom Score (OABSS) of 7 or higher
- Ability and willingness to provide informed consent
You will not qualify if you...
- Active urinary tract infection
- Stress urinary incontinence as the main diagnosis
- Pelvic organ prolapse stage II or higher
- History of pelvic radiation or surgery within the last 6 months
- Use of anticholinergics or beta-3 agonists in the past 4 weeks without willingness to undergo washout
- Pregnancy or breastfeeding
- Neuropathic diseases or psychological disorders
- History of urogenital cancer
- Uncontrolled diabetes mellitus (HbA1c greater than 6.8)
- Uncorrected blood clotting problems or severe cardiovascular disease
- Contraindication to solifenacin such as closed angle glaucoma
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mansoura Faculty of medicine
Al Mansurah, Dakahlia Governorate, Egypt, 35111
Actively Recruiting
Research Team
Y
Yahya H Elmorsy
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here